Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Transplantation, Cytomegalovirus Infections Clear all
Completed Phase 4 Interventional Results available

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

NCT01376804
View directory record Official record
Conditions
Kidney Transplantation, Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
4 Months to 16 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Gainesville, Florida • Los Angeles, Louisiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 23, 2026, 9:36 PM EDT
Not yet recruiting Phase 4 Interventional

Letermovir for R+ Study

NCT07706166
View directory record Official record
Conditions
Kidney Transplant, Liver Transplant
Interventions
Letermovir
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 23, 2026, 9:36 PM EDT
Recruiting Phase 3 Interventional

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

NCT06407232
View directory record Official record
Conditions
Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
Interventions
Letermovir
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 9:36 PM EDT
Not yet recruiting Phase 4 Interventional

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

NCT07571135
View directory record Official record
Conditions
CMV Infection, CMV, CMV Viremia, CMV Disease
Interventions
Letermovir, Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
Elisabeth Kincaide
Government
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

NCT01972035
View directory record Official record
Conditions
Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
Interventions
Valacyclovir, Valganciclovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 23, 2026, 9:36 PM EDT
Not listed Phase 1 Interventional

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 4 Interventional

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

NCT00034385
View directory record Official record
Conditions
Kidney Trasplant
Interventions
Valganciclovir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Not applicable Interventional

Study of Prophylactic Vs Preemptive Valganciclovir

NCT00374686
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Jul 23, 2026, 9:36 PM EDT
Completed No phase listed Observational

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

NCT01558037
View directory record Official record
Conditions
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Michael Ison
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 4 Interventional Results available

A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

NCT01663740
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Valganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Jul 23, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

NCT02439957
View directory record Official record
Conditions
Cytomegalovirus Disease, Kidney Transplant Infection
Interventions
Brincidofovir, Valganciclovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

NCT04225923
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo
Drug
Lead sponsor
Nobelpharma
Industry
Eligibility
18 Years to 76 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

NCT00045292
View directory record Official record
Conditions
Cancer
Interventions
acyclovir, acyclovir sodium, valacyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

NCT00002673
View directory record Official record
Conditions
Cancer
Interventions
infection prophylaxis and management
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2010 · Synced Jul 23, 2026, 9:36 PM EDT
Recruiting Phase 4 Interventional

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796
View directory record Official record
Conditions
Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Drug
Lead sponsor
Camille N. Kotton, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 23, 2026, 9:36 PM EDT
Completed No phase listed Observational

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

NCT03924219
View directory record Official record
Conditions
Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
Interventions
CMV T cell Immunity Assay
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 23, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

NCT02439970
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Brincidofovir, Valganciclovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 23, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

NCT03629080
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infection, Kidney Transplantation
Interventions
HB-101 vaccine, placebo
Biological
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • La Mesa, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 23, 2026, 9:36 PM EDT